The Trendlines Group Reports 2017 First Quarter Results

Misgav, Israel and Singapore, 9 May 2017 – The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries and associated companies, **"Trendlines"** or the "**Group**") an Israeli company focused on developing technology-based companies in the medical and agricultural fields, announced its financial results for the three months ended 31 March 2017 ("Q1 2017").

First Quarter 2017 Highlights:

Group Financials

- Fair value of portfolio was US$83.8 million at 31 March 2017, compared to US$83.7 at 31 December 2016
- Total current assets were US$14.6 million at 31 March 2017, compared to US$17.3 million at 31 December 2016
- Trendlines reports total income of US$1.2 million for Q1 2017, compared to total income of US$1.1 million in the three months ended 31 March 2016 ("Q1 2016")
- Total expenses were unchanged for Q1 2017, compared to Q1 2016 at US$2.6 million
- Pretax loss was US$1.4 million in Q1 2017, compared to a pretax loss of US$1.5 million in Q1 2016
- Net loss was US$1.6 million in Q1 2017, compared to a net loss of US$0.8 million in Q1 2016.

Corporate/Business Development

- Trendlines Medical Singapore officially launched on 22 February 2017
- Trendlines Medical Singapore receives a SG$2.2 million grant from SPRING Singapore, the enterprise development agency of the Singapore Ministry of Trade and Industry.
- Trendlines Labs signs agreement with Singapore General Hospital on product development and clinical trial of its stress urinary incontinence device with funding from the Singapore Israel Industrial Research and Development Foundation (SIIRD)

2017 First Quarter Financial Results

"We saw steady financial performance in the first quarter of 2017," said Steve Rhodes, Chairman and CEO of Trendlines. "We are pleased that our portfolio value held stable over the quarter at US$83.8 million and that expenses and pretax profitability levels remained virtually unchanged compared to the first quarter in 2016, despite the hiring of additional professional staff over the past 12 months to boost assistance to our portfolio companies."

For the first quarter of 2017, total Income was US$1.2 million, compared to total income of US$1.1 million in the first quarter of 2016. Total expenses were US$2.6 million at Q1 2017, the same level as in Q1 2016.

Trendlines recorded a pretax loss of US$1.4 million for Q1 2017, compared to a pretax loss of US$1.5 million in Q1 2016. The net loss for Q1 2017 was US$1.6 million, compared to a net loss of US$0.8 million in Q1 2016, tax expense in Q1 2017 was US$0.2 million versus a tax credit of US$0.7 million in Q1 2016.

Total current assets were US$14.6 million as at 31 March 2017, compared to US$17.3 million as at 31 December 2016. The decline was due to a decrease in cash and cash equivalents which were reduced mainly due to investments in our portfolio companies and operating expenses.

Total non-current assets were US$85.3 million at 31 March 2017, the same level as at 31 December 2016. Non-current assets were comprised mainly of investments in our portfolio companies which remained relatively unchanged as compared to 31 December 2016. During the quarter, there was a net increase of US$1.5 million in the fair value of some of our portfolio companies, taking into account our investment in some portfolio companies, results of fund raising exercises and general commercial or technological developments, which was offset by write offs of three portfolio companies, amounting to approximately US$1.4 million.

Equity attributable to equity holders of the Company totaled US$76.6 million at the end of the first quarter of 2017, compared to US$78.2 million at the end of 2016.

Commenting on portfolio company developments during the quarter, Chairman and CEO, Todd Dollinger, said: "We have had excellent clinical, regulatory and commercial developments in a number of our portfolio companies over the quarter. Gordian Surgical Ltd. received its first European purchase order and started its first procedures at US hospitals including Mount Sinai in New York and the Cleveland Clinic in both Ohio and Florida. S.T. Stent Ltd. successfully completed its first-in-human pilot study, while both CoreBone Ltd. and Headway Ltd. receive approval from the Israeli Ministry of Health to market their products in Israel. InPlant Technologies Ltd. signed a collaboration agreement with a multinational company to develop advanced crop protection products."

Mr. Dollinger continued, "I am pleased to report the recent investment in a new Israeli medical company, Limaca, which is based on a technology developed in Trendlines Labs. Limaca received the approval of the Israel Innovation Authority in the first quarter of 2017 and the investment was completed early in the second quarter. We expect further additions to the Trendlines' portfolio in the near future from both our Israeli incubators and from Trendlines Medical Singapore, which had its official launch during the first quarter; Eric Loh, Trendlines Medical Singapore's CEO, is leading our deal flow management and due diligence process in Singapore."

For full financial information, please see our announcement to the SGX: Unaudited Financial Statement and Dividend Announcement for the Three Months Ended 31 March 2017 (http://investors.trendlines.com/reports-and-presentations/2017).

About The Trendlines Group Ltd.
Trendlines is an innovation investment and commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

Issued for and on behalf of The Trendlines Group Ltd.
By Financial PR Pte Ltd.

For more information, please contact:
Romil SINGH / Reyna MEI
romil@financialpr.com.sg / reyna@financialpr.com.sg
Tel: (65) 6438 2990, Fax (65) 6438 0064

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.